Introgen Therapeutics, Inc.
Records under this name other than patents Introgen Therapeutics, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Introgen Therapeutics, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,668,905 | P53 vaccines for the treatment of cancers Formerly held Lapsed on the fee record Ended Mar 11, 2026 · High confidence | Lapsed on the fee record | Ended Mar 11, 2026 | High confidence |
| US 8,034,790 | Use of MDA-7 to inhibit pathogenic infectious organisms Formerly held Term ended Term ended Mar 26, 2025 · USPTO record | Term ended | Term ended Mar 26, 2025 | USPTO record |
| US 9,428,768 | Method for the production and purification of adenoviral vectors Term ended Term ended Nov 4, 2023 · USPTO record | Term ended | Term ended Nov 4, 2023 | USPTO record |
| US 7,235,391 | Formulation of adenovirus for gene therapy Formerly held Term ended Term ended Jul 8, 2023 · USPTO record | Term ended | Term ended Jul 8, 2023 | USPTO record |
| US 7,419,808 | Methods and compositions for the production of adenoviral vectors Formerly held Term ended Term ended May 15, 2023 · USPTO record | Term ended | Term ended May 15, 2023 | USPTO record |
| US 7,732,129 | Method for the production and purification of adenoviral vectors Formerly held Lapsed on the fee record Ended Jun 8, 2022 · USPTO record | Lapsed on the fee record | Ended Jun 8, 2022 | USPTO record |
| US 7,888,097 | Formulation for adenovirus storage Formerly held Term ended Term ended Feb 12, 2021 · USPTO record | Term ended | Term ended Feb 12, 2021 | USPTO record |
| US 7,888,096 | Liquid adenovirus formulations Formerly held Term ended Term ended Jan 3, 2021 · USPTO record | Term ended | Term ended Jan 3, 2021 | USPTO record |
| US 10,293,056 | Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases Formerly held Term ended Term ended May 24, 2020 · USPTO record | Term ended | Term ended May 24, 2020 | USPTO record |
| US 6,689,600 | Formulation of adenovirus for gene therapy Formerly held Term ended Term ended Nov 16, 2019 · USPTO record | Term ended | Term ended Nov 16, 2019 | USPTO record |